Pitavastatin tablets to reduce cholesterol has received tentative approval from the United States Food and Drug Administration (USFDA).
The United States Food and Drug Administration (USFDA) has tentatively approved the cholesterol lowering Pitavastatin tablets from Lupin Pharmaceuticals. "Pharma Major Lupin announced today that it has received tentative approval for its Pitavastatin tablets, 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA) to market a generic version of Kowa Company Limited's (Kowa) Livalo Tablets 1 mg, 2 mg and 4 mg," the pharmaceutical company said in a regulatory filing to the BSE.
‘Cholesterol-lowering Pitavastatin tablets from Lupin Pharmaceuticals has received the United Stated Food and Drug Administration (USFDA) approval.’
"Pitavastatin tablets are indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia," it added. Source-IANS